Max Healthcare Institute has announced that its board of directors approved a share purchase agreement for the complete acquisition of Yerawada Properties Private Limited during their meeting held on December 18, 2025. This strategic move is part of the company's ambitious plan to establish a significant healthcare presence in Pune with a ₹1,020 crore investment.

Board Meeting and Acquisition Approval

The board meeting, which commenced at 10:30 AM IST and concluded at 10:55 AM IST, approved the proposal to enter into a share purchase agreement for acquiring 100% equity stake in Yerawada Properties Private Limited (YPPL). The acquisition will be executed in a step-up manner and will conclude upon receipt of Occupancy Certificate for the planned hospital building.

Target Company Background

Yerawada Properties Private Limited was initially incorporated as a Limited Liability Partnership on February 19, 2024, and was converted into a company under the Companies Act, 2013 with effect from November 14, 2025. The company is engaged in real estate development business and owns 1.68 acres parcel of freehold land located in Yerawada, Pune.

Phased Acquisition Structure

The purchase of equity stakes will be carried out in a structured manner. In the first tranche, Max Healthcare Institute will acquire 100% of the Class A equity shares representing 100% of the voting rights and 50.22% of the economic interest in YPPL. Subsequently, the company will acquire 100% Class B Equity Shares in a phased manner over a period of 4 years.

Hospital Development Project

The board has also accorded approval for setting up a 450-bedded super specialty hospital on the land owned by YPPL. The facility will be developed in Yerawada, Pune, which is described as a prime locality in the centre of the city. The land parcel has the capacity to accommodate the planned hospital development.

Investment and Financing Details

The aggregate spend of up to ₹1,020 crore includes YPPL shares acquisition, construction, equipment cost, stamp duty, registration charges, and other associated expenses. The company plans to finance this investment through a mix of internal accruals and term loans. This represents a significant expansion of Max Healthcare's existing network capacity.

Strategic Market Expansion

This development represents Max Healthcare Institute's strategic expansion into Maharashtra's healthcare sector. The company cites Pune as a thriving city with a large population and growing middle class experiencing surge in demand for quality healthcare services. The hospital will cater to healthcare needs of population living in Pune and surrounding regions, positioning the company to serve western India's growing metropolitan healthcare market. The proposed transaction is not a related party transaction, and no government or regulatory approval is required for the acquisition of shares in YPPL.

Max Healthcare Institute Limited , a leading healthcare provider in India, has reported impressive financial results for the second quarter of fiscal year 2026, demonstrating consistent growth and strategic expansion initiatives.

Key Financial Highlights

Max Healthcare delivered strong performance in Q2 FY26, with significant year-on-year improvements across key financial metrics:

The company's robust financial performance extends its track record to 20 consecutive quarters of consistent growth, showcasing its resilience and operational efficiency in the healthcare sector.

Expansion Initiatives

Max Healthcare continues to focus on strategic expansion to enhance its capacity and service offerings:

1. Max Mohali: Commissioned a new 160-bed brownfield tower, including an additional radiation oncology program.
2. Nanavati-Max: A 268-bed brownfield tower is set to be commissioned, further expanding the hospital's capacity.
3. Max Smart: A 400-bed brownfield tower is expected to be ready for commissioning within the next 30 days.

These expansions are part of Max Healthcare's ongoing efforts to increase its bed capacity and improve its ability to serve more patients across its network.

CGHS Price Revisions

The company anticipates a favorable impact from the recent Central Government Health Scheme (CGHS) price revisions:

• Expected benefit: Over 200.00 crore once fully implemented
• Implementation status: Partially implemented, with complete rollout expected soon

This price revision is likely to positively affect Max Healthcare's revenue from government-sponsored healthcare schemes, potentially boosting its institutional business segment.

Financial Performance Analysis

Examining the quarterly financial data reveals several positive trends:

1. Revenue Growth: The company's revenue increased by 24.03% compared to the same quarter last year, reaching 2,168.40 crore.
2. Profitability Improvement: Net profit saw a substantial increase of 74.34% year-on-year, rising to 491.30 crore.
3. Operational Efficiency: The Operating Profit Margin (OPM) improved slightly to 26.93%, up from 26.39% in the same quarter last year.
4. Earnings Per Share (EPS): EPS showed significant growth, increasing by 74.14% to 5.05.

Outlook

Max Healthcare's consistent performance and strategic expansions position it well for continued growth in the Indian healthcare sector. The company's focus on brownfield expansions and operational efficiency improvements, coupled with favorable regulatory changes like CGHS price revisions, are likely to support its growth trajectory in the coming quarters.

Investors and stakeholders should note that while the company has shown strong performance, the healthcare sector remains subject to various external factors, including regulatory changes and broader economic conditions. As always, it is advisable to consider a diverse range of factors when making investment decisions.